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Supplementary Table 1 : SEGRAM-mediated effects on GR-mediated gene repression and activation 
mechanisms in vitro or ex vivo 
SEGRAM Cell line or type, species 
Effect of SEGRAM on genes/proteins that are 
ref 
Repressed by GCs  Elevated by GCs  
RU24858 A549, h 
 PGE2 (IC50= 53.9 ± 12.8 nM), 
IL-8 (IC50= 128 nM), COX-2, 
IL-1β 
 2×GRE-luc (12% eff),  [1] 
 MG 63, h  OPG (IC50=58±16 nM; Emax,obs=75±13 %) 
 [2] 
 FOB, h  OPG (IC50=973±205nM; Emax,obs=72±3%) 
 RANKL [2] 
Org214007-0 CHO, TT hGR, ha   
 MMTV-luc (EC50 5.1±1.6 
nM; 32±8.1% eff)   [3] 
 U2OS, ST GR, h 
 MCP1 (IC50 =0.36±0.19nM; 
81±16% eff)    [3] 
 THP-1, h 
 MCP1 (IC50 =23.5±9.3nM; 
44±8% eff), IL-6 (IC50 
=9.3±2.1nM; 78±9% eff), IL-8 
(IC50 =11.0±3.1nM; 74±10% eff)   
 FKPB51 (EC50 8.0±5.3 
nM; 42±8% eff), GILZ (EC50 
13.7±11.8 nM; 13±5% eff), 
DUSP1 (EC50 6.4±4.1 nM; 
41±6% eff)   
[3] 
 whole blood, h 
 TNFα (IC50 =50±19nM; 
68±8.7% eff), IL-5 (IC50 
=14.45±3.2nM; 64±11% eff); 
 G-CSF (EC50 186.2±63 










 MMP1 (120% eff)  [3] 
AL-438 HepG2, TT hGR, h E-selectin-luc  TAT3-luc [4] 
 COS-1, TT hGR, s 
 NF-κB-luc (IC50 =13±5nM; 
84±3% eff) 7xAP1-luc 
(IC50=0.05±0nM; 58±3% eff)  
 pTAT-GRE-E1B-luc (EC50 
8±3 nM; 67±12% eff)   [5,6] 
 ATDC5, m  IL-6 
≈ Aggrecan  [7] 
 MG 63, h 
 OPG (IC50=109 ± 41nM ; 
Emax,obs=52 ± 8%)  
≈ osteocalcin 
 [2,4] 
 FOB, h  OPG (IC50=75 ± 8nM; Emax, 
obs=45 ± 7% 
 RANKL [2] 
 skin fibroblasts, h  IL-6  aromatase [4] 
Compound A COS-1, TT GR, s 
 NF-κB-luc (IC50=1543nM; 
29±5 % eff), IL6-luc, CBG-luc ≈ TAT-(GRE)2-E1B-luc [5,6,8] 
 L929sA, m 
 IL-6, E-selectin-luc, (NF-κB)3-
luc, TNFα, MCP1, IκBα 
≈ c-jun 
 AP-1-luc, Colla3-luc, MMP13 
≈ (GRE)2-luc, DUSP1 [9,10] 
 TC-10, m  IL-6  [10] 
 A549, h  IL-8, NF-κB-luc, CCL2, CCL5, eotaxin 
≈ (GRE)2-luc, DUSP1, 
GILZ, PAP [11,12] 
 LNCaP-GR, ST GR, h  ≈ MMTV-luc, TAT-luc [13] 




 HEK293T, TT GR, h SBE4-luc, (NF-κB)3-luc ≈ GRE-luc [10,14,15] 
 CT5.3hTERT, h 
 vimentin, RANTES, ICAM, 
HGF 
≈ MCP1, IL-1β, TNFα, N-
Cadherin, TGFβ, TenascinC 
≈ GILZ [16] 
 RAW 264.7, m TNFα, IL-6, iNOS IL-10 [17] 
 Caco-2, TT GR, h 
IL-8 
EGFR 
≈ DUSP1, Annexin-1, GRE-
luc [14,15] 
 MEF, m  MMP13  [18] 
 Saos-2, h 
 MMP1, MMP9, I-L8, TNFα, 
MCP1 
≈ OPG 
≈ RANKL [19] 
 MLO-Y4, osteocyte, h ≈ OPG ≈ RANKL, DKK-1 [20] 
 fibroblast-like synoviocytes, h 
 IL-1β, TNFα, MMP1, MMP3, 
IL-6, IL-8, MCP1 
≈ OPG 
≈ RANKL, TAT, PCOLCE2, 





 IL-6, IL-8, MMP1, MMP3 ≈ leptin [23] 
 bone-marrow stromal cells, h ≈ ALP, RUNX ≈ DKK-1 [20,24] 
 primary osteoblast, m 
 CXCL10, IL-6 
≈ IL-11, Runx2, Col1a1, Bglap2, 
osteocalcin 
 [19] 
 primary osteoblast, h  IL-6, TNFα, IL-1β, OPG  RANKL [24] 
 arthritic mice, PBMC, m  IFNγ, TNF  [25] 
 primary microglia, m  IL-1β ≈ GILZ, FKBP51, DUSP1 [26] 
 primary astrocytes, m  TNF ≈ GILZ, FKBP51, DUSP1 [26] 
 Encephalito-genic T cells, r  IFNγ, IL-17 ≈ GILZ [18] 
 PBMCs, h 
 IL-6, IL-8, MCP-1, IL-2,    







 TNF-α, IL-1β 
≈ IL-2, IL-17, IL-6  IFN-γ [27] 
Compound 10 HEK293, TT hGR, h  
 GRE-luc (EC50 
2.1±00.86nM; 53% eff) [28] 
 CCD-39SK, h  IL-6 (IC50=4.38±0.384nM)   [28] 
 U937, h  TNFα (IC50=19.1±9.3 nM)  [28] 
LGD-5552 HepG2, TT hGR, h 
E-selectin luc (IC50=2 nM; 
100% eff), IL-6-luc (IC50=22 
nM; 22% eff) 
 [29,30] 
 CV1, TT hGR, s  
≈ MMTV-luc (EC50, 1nM; 
5% eff) [29] 
 H4IIE, r  
PEPCK 
≈PDK4 [30] 




 HeLa, h   MMTV-luc (EC50= 184nM; 25% eff) [31] 
 A549, h   MMTV-luc (EC50= 240nM; 32% eff) [31] 
 whole blood, h 
 TNFα (Emax= 40±12 %), IL-6 
(Emax= 15±5 %), IFNγ (Emax= 
90±14 %), IL-1β (Emax= 
41±12%) 
  [31] 
 whole blood, r  TNFα (Emax= 71±6 %), IL-6 (Emax= 88±1 %) 
 [31] 
ZK216348 HEK293T, TT GR, h  SBE4-luc ≈ GRE-luc [14,15] 





 IEC-6, r ≈ TGFβ  [15] 
 H4IIE-C3, r  TAT (EC50=95 nM; 88% eff) [32] 
 THP1, h 
 IL-8 (IC50=35 ± 10 nM; 52 ± 
15 % eff)  [32] 
 MG 63, h  OPG (IC50=352 ± 186nM; Emax,obs=44 ± 9%) 
 [2] 
 FOB, h  OPG (IC50=508 ± 67nM; Emax,obs=50 ± 2%) 
 RANKL [2] 
 PBMC, h 
 IL-12 p70 (IC50=52 nM; 89% 
eff), TNFα (IC50=89 nM; 63 % 
eff), IL-6, IL-8, MCP-1 
 [14,15,32] 
Mapracorat HepG2, h   TAT (EC50=71.2±64.6 nM; 62±7% eff) [33] 
 HeLa, h  Collagenase-luc (IC50=1.6±0.3 nM; 89±84% eff) 
 MMTV-luc (EC50=7.1±3.2 













 conjunctival fibroblasts, h 
 eotaxin-1 (IC50=1.0±0.1 nM), 
eotaxin-3 (IC50=0.9±0.3 nM), 
RANTES (IC50=1.0±0.5 nM), 
IL-6 (IC50=1.2±0.4 nM), MCP1 
(IC50=0.3±0.3 nM), IL-8 
(IC50=2.4±7.7 nM), ICAM-1 
(IC50=7.2±3.9 nM) 
 [34] 
 PBMC, h 
 IL-12p40 (IC50=7.2±2.0 nM; 
83±8 % eff), IFNγ (IC50= 
10.3±7.8 nM; 88±6 % eff) 
 [33] 
 primary keratocytes, h 
 IL-6, IL-8, MCP1, COX2, 
PGE2 
 [35] 
PF-802 A549, h  IL-6 (IC50 = 0.20 nM; 78% eff)   [36] 
 whole blood, h  IFNγ  [36] 
 primary hepatocytes, h   PEPCK, TAT [36] 





CI, confidence interval; h, human; ha, hamster; m, murine; r, rat; ref, reference; s, simian; ST, stably transfected; 
TT, transiently transfected; , increased levels of this gene/protein; , decreased levels of this gene/protein;  ≈, 
no significant activity on this gene/protein. 
% eff is the percentage efficiency as compared to a steroid control (dexamethasone or prednisolone) 
Emax is the fitted percent inhibition at infinite dose relative to the with and without LPS controls 
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